|   From the Trenches

Setting Up A US Biotech Subsidiary: Cambridge, Old England To Cambridge, New England

It’s January on a ship in the South Pacific. Instead of enjoying hula and coconuts, I’m struggling to type left-handed in response to an emailed offer to set up and lead the US subsidiary of Bicycle Therapeutics. My right hand came off second best from a misunderstanding with a Polynesian Rottweiler. Yes, Tahiti has dog bites as well as blue lagoons and black volcanic beaches. But importantly – for me – not rabies.

This post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Digital Health: The Convergence Of Consumer Devices And Clinical Applications

Those of us in biotech tend to focus our attention on drug discovery and development, but it is also important to take note of important advances in orthogonal areas, such as digital health.

This post was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Birth: An Epic Day Of Bacterial Invasion

When I was a graduate student, I listened to the famous developmental biologist Lewis Wolpert say, “It is not birth or marriage or even death that are ‘the’ key milestones of our life, it is gastrulation.” At that time, I smiled proudly as I was dedicating my pre-doctoral  life to study drosophila blastulas and their future “consequential” steps. Now that I am in my 50s, I found myself re-examining key milestones in life. This was a thorough and painful process of which I will spare you the details, but after all that middle-age drama, my scientific mind took over and brought me to a good, comfortable place. I concluded that I disagreed with Professor Wolpert because I believe the most important milestone in life is birth.

This post was written by JC Gutierrez-Ramos, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   News

Biotech Vet MacKay Grabs a $25M A Round to Back a Gene Therapy Upstart

After completing an 11-year stint as CEO of Organogenesis, Geoff MacKay gathered a small, experienced team together and began a global search for new gene therapies at AvroBio. Earlier this year, they landed seed financing from Atlas Venture after zeroing in on the work of a pair of scientists in Toronto. And today he landed a $25 million A round to get his two lead programs into the clinic later this year.

Read more.


  |   News

More Gene Therapy Momentum as Startup Avrobio Grabs $25M From Atlas, SV

Gene therapy developers are on bit of a roll. Last week saw the release of promising data on gene therapies for hemophilia and the acquisition by Pfizer of a startup dedicated to the technology. And now another recently launched company, Avrobio, just grabbed a $25 million round of funding.

Read more.